The Role of the Glutamatergic System in the Extinction of Conditioned Reinforcement Processes (SFB636D6)
|ClinicalTrials.gov Identifier: NCT00926900|
Recruitment Status : Unknown
Verified November 2011 by Central Institute of Mental Health, Mannheim.
Recruitment status was: Recruiting
First Posted : June 24, 2009
Last Update Posted : November 28, 2011
The aim of this project is to explore whether the extinction of cue-reactivity following a cue-exposure based intervention in volunteers with an alcohol dependence is facilitated by drugs that increase NMDA-receptor function.
It is hypothesised that targeted treatment with D-Cycloserine prior to each extinction training session enhances the effects on cue-reactivity.
Further, a significant correlation between the reduction of cue-reactivity and both reduced craving and relapse probability is expected.
|Condition or disease||Intervention/treatment||Phase|
|Alcohol Drinking||Drug: D-cycloserine Drug: Placebo||Phase 2 Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||80 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Primary Purpose:||Basic Science|
|Official Title:||The Role of the Glutamatergic System in the Extinction of Conditioned Reinforcement Processes|
|Study Start Date :||March 2009|
|Estimated Primary Completion Date :||April 2012|
|Active Comparator: D-cycloserine||
50 mg at approximately 1.5 hours prior to cue-exposure training sessions
|Placebo Comparator: Placebo||
- reduction in cue-reactivity to alcohol-associated stimuli assessed by functional magnetic resonance imaging [ Time Frame: following completion of cue-exposure therapy ]
- time to first severe relapse to alcohol consumption [ Time Frame: at 3 and 6 months after treatment completion ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00926900
|Contact: Falk Kiefer, Professor||+49 621 1703 firstname.lastname@example.org|
|Central Institute of Mental Health||Recruiting|
|Mannheim, Germany, 68159|
|Contact: Falk Kiefer, Professor +49 621 1703 3522 email@example.com|
|Principal Investigator: Falk Kiefer, Professor|
|Principal Investigator:||Falk Kiefer, Professor||Central Institute of Mental Health, Department of Addictive Behavior and Addiction Medicine|